MedPath

Nanoscope Therapeutics Enhances Vision Restoration Therapy with CatCh Technology License

• Nanoscope Therapeutics has licensed the CatCh technology from Max Planck Innovation to boost the light sensitivity of its MCO-010 gene therapy. • MCO-010, a tri-protein fusion complex, targets inherited retinal degenerative diseases like retinitis pigmentosa and Stargardt disease, showing promise in clinical studies. • The CatCh technology, integrated into MCO-010, enhances its light-activated properties, potentially improving vision restoration in various settings. • Nanoscope is in discussions with the FDA to explore accelerated approval pathways for MCO-010, aiming to address unmet needs in severe retinal conditions.

Nanoscope Therapeutics Inc. has secured a license for the CatCh technology from Max Planck Innovation, a move poised to enhance its MCO-010 gene therapy for inherited retinal diseases. This patented technology is designed to increase the light sensitivity of MCO-010, a tri-protein fusion complex, which Nanoscope is developing to restore vision in patients with genetically-caused visual impairments.
Nanoscope has already conducted successful clinical studies on MCO-010 for retinitis pigmentosa (RP) and Stargardt disease, two leading inherited retinal degenerative diseases. The company is now seeking approval for the therapy and plans to expand its application to broader therapeutic indications.

MCO Platform and CatCh Technology

Dr. Samarendra Mohanty, Co-Founder & President of Nanoscope Therapeutics, highlighted the potential of the enhanced MCO platform, stating, "Our agreement with Max Planck Innovation allows us to transform groundbreaking scientific discoveries into effective therapeutic solutions...we are on the cusp of treating patients with high unmet needs and sustainably improving their quality of life."
Dr. Mareike Göritz, Patent and Licensing manager at Max Planck Innovation, added, "The advanced properties of CatCh in combination with Nanoscope's proprietary technology make this a very promising approach for gene therapy treatment of retinitis-related visual impairments."
The CatCh (calcium-transporting channelrhodopsin) technology, developed by Prof. Ernst Bamberg and colleagues at the Max Planck Institute for Biophysics, is a mutant of Channelrhodopsin-2 with improved properties, offering faster kinetics and increased blue light sensitivity.

Therapeutic Application and Clinical Testing

The licensed CatCh technology has been integrated by Nanoscope Therapeutics as one of three subunits of the MCO-010 fusion protein. The MCO platform is also being tested in non-human primates with geographic atrophies (GA) secondary to advanced age-related macular degeneration (AMD).
Nanoscope Therapeutics is actively reviewing the development and approval pathway for MCO-010 and is in discussions with the US Food and Drug Administration (FDA) to explore possible accelerated pathways to market.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Extends Review Timeline for Neurotech's NT-501 MacTel Treatment

Neurotech Pharmaceuticals announced an update on its biologics license application for NT-501, a treatment for macular telangiectasia type 2 (MacTel), with the FDA extending the review period by three months to March 18, 2025, to allow for additional data evaluation.

Advancements in Retina and Vitreous Treatments Highlighted in Recent Studies and Collaborations

Recent developments in the treatment of retinal diseases include strategic collaborations, clinical trials, and studies highlighting advancements in personalized treatment and the increasing prevalence of retinopathy of prematurity.

Ocugen's OCU400 Shows Promise in Retinitis Pigmentosa Treatment with Positive Clinical Data and Regulatory Milestones

Ocugen's OCU400 gene therapy demonstrated a statistically significant improvement in low-luminance visual acuity in patients with retinitis pigmentosa (RP).
The European Medicines Agency (EMA) has granted OCU400 an Advanced Therapy Medicinal Product (ATMP) classification, expediting its regulatory review process.

CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial

CaaMTech received positive feedback from U.S. regulators for its CT-4201 psilocin prodrug program, which includes a strategy for functional unblinding in clinical trials.
The validation streamlines the clinical development of CT-4201, a psilocin prodrug with enhanced pharmacokinetics, for treating Major Depressive Disorder (MDD).

FDA Clears HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 for nAMD

The FDA has cleared HuidaGene Therapeutics' IND application for HG202, a CRISPR/Cas13 RNA-editing therapy, for neovascular age-related macular degeneration (nAMD).
HG202 targets VEGF-A mRNA using a non-receptor binding pathway, potentially addressing resistance to current anti-VEGF therapies.

Nanoscope's MCO-010 Gene Therapy Shows Sustained Vision Improvement in Retinitis Pigmentosa Trial

Nanoscope Therapeutics' MCO-010 gene therapy significantly improved visual acuity in retinitis pigmentosa patients compared to the control group in a Phase 2b trial.
The RESTORE trial demonstrated statistically significant and durable vision improvement over a two-year period, with some patients showing clinically meaningful gains.

Optogenetic Gene Therapy MCO-010 Shows Promise in Retinitis Pigmentosa

MCO-010, a novel optogenetic gene therapy, has demonstrated significant vision improvement in patients with severe retinitis pigmentosa in a Phase 2b/3 trial.
The mutation-agnostic approach of MCO-010 targets surviving retinal cells, potentially offering a broader treatment option compared to gene-specific therapies like Luxturna.

Nanoscope Plans BLA Submission for MCO-010 Gene Therapy in Retinitis Pigmentosa

Nanoscope Therapeutics plans to submit a Biologics License Application (BLA) to the FDA in Q1 2025 for MCO-010 to treat retinitis pigmentosa.
MCO-010, a gene-agnostic optogenetic therapy, has shown significant vision improvement in advanced RP patients in Phase 2b/3 RESTORE trial.

Nanoscope Therapeutics to Advance MCO-010 for Stargardt Disease to Phase 3 Trial Following FDA Meeting

Nanoscope Therapeutics' MCO-010 gene therapy is set to advance to a Phase 3 registrational trial for Stargardt Macular Degeneration after a productive meeting with the FDA.
The FDA has provided input on the Phase 3 trial design, which will assess MCO-010's safety and efficacy using best-corrected visual acuity as the primary endpoint.

Entero Therapeutics to License AI-Powered Clinical Trial Compliance Tech from Data Vault

Entero Therapeutics will license Data Vault's QOLPOM and FotoDigm platforms to enhance clinical trial compliance, particularly for its Phase 3 latiglutenase trial.
The technology employs machine learning and machine vision to improve remote patient monitoring and data collection in clinical trials.

Reference News

[1]
Nanoscope Therapeutics Inc. acquires a license for the CatCh technology - Modern Retina
modernretina.com · Oct 13, 2024

Nanoscope Therapeutics acquired CatCh technology from Max Planck Innovation to enhance light sensitivity of MCO-010, a g...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy